Previously located in Wilmington DE and now relocated to Brandford. CT, IsoPlexis (NASDAQ:ISO) - an active SBIR player for some time - is a life sciences company developing a diagnostic platform to measure cellular immune responses in patients. With research areas emcompassing cell engineering & therapy, checkpoint & combination Immunotherapies, vaccines & immunology research, Iinflammatory & autoimmune disease and solid tumor & oncology, the companys single-cell immune biomarkers are used to detect cellular responses at the single cell level to help determine individual therapeutic response. Originally spun out of Yale, the firm is developing a diagnostic platform to accelerate immunology research and therapeutic development assessing safety and efficacy of therapeutics, and monitoring disease progression - effectively enabling improved therapeutic development and informing physician decisions. Mostly focused to highly sensitive, multiplexed single-cell analysis tools for the life sciences, the firm's specialties include 'secretomic' analysis (in situ proteomics) for applications in immune monitoring, vaccine response evaluation, personalized medicine, adoptive immune therapies, stem cell research (including iPS), and oncology (including diagnostic tumor progression).